🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04686097
Recruiting Not applicable

Percutaneous Electrocoagulation Versus Sclerosing Foam for Patients With Incompetent Perforating Veins

NCT04686097 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Started
2021-01-01
Last updated
2026-07-24

Condition(s) studied

Incompetent Perforating Veins

Investigational drug(s) / intervention(s)

treatment: puncture of coagulationtreatment: sclerosing agent injected

treatment: puncture of coagulation: ultrasound-guided puncture of coagulation

treatment: sclerosing agent injected: ultrasound-guided sclerosing agent injected

Study summary

This study aimed to compare the efficacy of punctured electrocoagulation and sclerotherapy in the treatment of incompetent perforator veins.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: (1) outward flow of less than 500 ms duration, with a diameter of \>3.5 mm; (2) According to the CEAP classification method specified by the International Venous Federation, patients with C4b\~C6 grades are included. Exclusion Criteria: (1)age \< 18 years or age \> 80 years; (2)with malignant tumors and life expectancy \< 1 year; (3)with past or current history of deep vein thrombosis and/or pulmonary embolism in the lower extremities; (4)with congenital venous malformations (K-T syndrome, arteriovenous fistula and etc.; (5)inability to walk, long-term braking, restrictive bed rest; severe ischemia of lower extremities or diagnosed severity of peripheral artery occlusive disease; (6)according to the researcher's judgment, it is not suitable for foam hardener and puncture coagulation treatment; (7)allergic to the drugs and equipment materials involved in the research; (8)with inferior vena cava and/or iliac vein stenosis or occlusion; (9)with autoimmune disease, receiving chemotherapy, hormone therapy or immunomodulatory treatment; (10)other underlying severe diseases; women who are pregnant, breastfeeding or have pregnancy plans during the study period; (11)the patient cannot cooperate to complete the inspection and follow-up required by the study.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Anhui Provincial Hospital Hefei Anhui Suspended
Yantai Yuhuangding Hospital Yantai Shandong Suspended
Zhongshan Hospital affiliated to Fudan University Shanghai Shanghai Municipality Suspended
Sir Run Run Shaw Hospital Hangzhou Zhejiang Suspended
The second affiliated hospital of zhejiang university school of medicine Hangzhou Zhejiang Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04686097 on ClinicalTrials.gov ↗ ← All trials in China